[go: up one dir, main page]

WO2006039399A3 - Staufen 1 (stau1) - mediated mrna decay - Google Patents

Staufen 1 (stau1) - mediated mrna decay Download PDF

Info

Publication number
WO2006039399A3
WO2006039399A3 PCT/US2005/035011 US2005035011W WO2006039399A3 WO 2006039399 A3 WO2006039399 A3 WO 2006039399A3 US 2005035011 W US2005035011 W US 2005035011W WO 2006039399 A3 WO2006039399 A3 WO 2006039399A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrna decay
staufen
mediated mrna
stau1
staul
Prior art date
Application number
PCT/US2005/035011
Other languages
French (fr)
Other versions
WO2006039399A2 (en
Inventor
Lynne E Maquat
Yoon Ki Kim
Original Assignee
Univ Rochester
Lynne E Maquat
Yoon Ki Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Lynne E Maquat, Yoon Ki Kim filed Critical Univ Rochester
Publication of WO2006039399A2 publication Critical patent/WO2006039399A2/en
Publication of WO2006039399A3 publication Critical patent/WO2006039399A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed are compositions and methods for treating subjects with conditions resulting from Stau 1 -mediated mRNA decay, screening for, and manufacturing those therapeutic agents. Described herein are novel mRNA decay mechanisms that involves mammalian Staufen (Stau)l, the nonsense-mediated mRNA decay (NMD) factor Upfl, and a termination codon. It is shown that Staul binds directly to Upfl and can elicit mRNA decay when tethered downstream of a termination codon. Also disclosed is the new pathway as a means for cells to down-regulate the expression of Staul-binding mRNAs.
PCT/US2005/035011 2004-09-29 2005-09-29 Staufen 1 (stau1) - mediated mrna decay WO2006039399A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61407104P 2004-09-29 2004-09-29
US60/614,071 2004-09-29
US64684405P 2005-01-25 2005-01-25
US60/646,844 2005-01-25

Publications (2)

Publication Number Publication Date
WO2006039399A2 WO2006039399A2 (en) 2006-04-13
WO2006039399A3 true WO2006039399A3 (en) 2007-04-19

Family

ID=36143051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035011 WO2006039399A2 (en) 2004-09-29 2005-09-29 Staufen 1 (stau1) - mediated mrna decay

Country Status (1)

Country Link
WO (1) WO2006039399A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2626437A3 (en) 2008-05-14 2013-12-11 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US9206479B2 (en) 2011-02-09 2015-12-08 University Of Rochester Methods and compositions related to Staufen 1 binding sites formed by duplexing Alu elements
WO2016179043A1 (en) 2015-05-01 2016-11-10 Dermtech, Inc. Non-invasive skin collection system
EP3551641A4 (en) * 2016-12-08 2021-01-13 University of Utah Research Foundation Staufen1 agents and associated methods
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
JP2021527649A (en) 2018-06-14 2021-10-14 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ Staufen1 regulator and related methods
JP2022524641A (en) 2019-03-26 2022-05-09 ダームテック，インク． New gene classifiers and their use in skin cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERRAIUOLO ET AL: "A role for the elF4E-binding protein 4E-T in P-body formation and mRNA decay", THE JOURNAL OF CELL BIOLOGY, vol. 170, 12 September 2005 (2005-09-12), pages 913 - 924, XP003010912 *
KIM ET AL: "Mammalian Staufen1 recruits Upfl to specific mRNA 3'UTR so as to elicit mRNA decay", CELL, vol. 120, 28 January 2005 (2005-01-28), pages 195 - 208, XP003010913 *
MEYER E.L. ET AL: "Staufen does double duty", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 12, 4 April 2005 (2005-04-04), pages 291 - 292, XP003010911 *

Also Published As

Publication number Publication date
WO2006039399A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
Li et al. Bibliometric analysis on global Parkinson's disease research trends during 1991–2006
WO2012109476A3 (en) Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements
WO2008013664A3 (en) Methods of producing pancreatic hormones
WO2006039399A3 (en) Staufen 1 (stau1) - mediated mrna decay
PL2138128T3 (en) Hernial prosthesis and method for manufacturing same
SG149061A1 (en) Definitive endoderm
NZ602248A (en) Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
WO2007047583A3 (en) Conditionally immortalized long-term stem cells and methods of making and using such cells
WO2003078588A3 (en) Primitive and proximal hepatic stem cells
TW200514555A (en) γ -aminobutyrc acid enrichment method and grain obtaining by the method thereof
Kumar et al. Hairy root induction in Helicteres isora L. and production of diosgenin in hairy roots
WO2008064306A3 (en) Methods and compositions relating to islet cell neogenesis
ZA200706430B (en) Wire for refining molten metal and associated method of manufacture
WO2010090843A3 (en) Gingiva derived stem cell and its application in immunomodulation and reconstruction
CN101603027A (en) Method for inducing human bone marrow mesenchymal stem cells to differentiate into islet-like cells in vitro
WO2009009114A3 (en) Compositions and methods for treating and diagnosing cancer
WO2009062260A8 (en) Therapy for multiple sclerosis
Yu et al. Transplantation of insulin-producing cells to treat diabetic rats after 90% pancreatectomy
WO2006119346A3 (en) Ketocarotenoids from adonis palaestina
CN101942467A (en) Method for enhancing content of tanshinone in salvia miltiorrhiza hairy root by double-key enzyme genetic transformation
WO2008021502A3 (en) Methods and compositions for removing cells from collection material
Hou et al. Metabolic engineering of Saccharomyces cerevisiae for de novo dihydroniloticin production using novel CYP450 from neem (Azadirachta indica)
CN101362791A (en) A kind of steroidal alkaloid veratramine and its preparation method and antihypertensive application
Printz Agencies join forces to boost the number of veterans in cancer clinical trials: A new program is helping to make National Cancer Institute-sponsored trials more accessible to a vulnerable population
WO2008054693A3 (en) Uses of tetrahydrobiopterin and derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase